X T L Biopharmaceuticals Ltd (XTLB) has a current Price-to-Book (P/B) ratio of -11311.32. Compared to its 3-year average P/B ratio of -440.54, the current P/B ratio is approximately 2467.60% higher. Relative to its 5-year average P/B ratio of -114.73, the current P/B ratio is about 9758.81% higher. X T L Biopharmaceuticals Ltd (XTLB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.51%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.35%, the current FCF yield is about -100.00% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XTLB competitors is 1.92, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB.O) exhibits a P/S ratio of 0.02, which is -98.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XTLB increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XTLB in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XTLB currently overvalued or undervalued?

What is X T L Biopharmaceuticals Ltd (XTLB) fair value?

XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 0.63 to 5.30 according to relative valuation method.

How does XTLB's valuation metrics compare to the industry average?

The average P/S ratio for XTLB's competitors is 1.92, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.02, which is -98.97% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Mar 02 2026?

As of Mar 02 2026, X T L Biopharmaceuticals Ltd (XTLB) has a P/B ratio of -11311.32. This indicates that the market values XTLB at -11311.32 times its book value.

What is the current FCF Yield for X T L Biopharmaceuticals Ltd (XTLB) as of Mar 02 2026?

As of Mar 02 2026, X T L Biopharmaceuticals Ltd (XTLB) has a FCF Yield of 0.00%. This means that for every dollar of X T L Biopharmaceuticals Ltd's market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Mar 02 2026?

As of Mar 02 2026, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/E ratio of 1.20. This means the market is willing to pay $1.20 for every dollar of X T L Biopharmaceuticals Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Mar 02 2026?

As of Mar 02 2026, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/S ratio of 0.02. This means the market is valuing XTLB at $0.02 for every dollar of expected revenue over the next 12 months.

XTLB Valuation